Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases

Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action

(2013) Jonathan E. Campbell et al.   Cell Metabolism

Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence

(2013) Jessica Freiherr et al.   CNS DRUGS

Lixisenatide: First Global Approval

(2013) Shelley Elkinson et al.   DRUGS

Exenatide and the treatment of patients with Parkinson’s disease

(2013) Iciar Aviles-Olmos et al.   JOURNAL OF CLINICAL INVESTIGATION

Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress

(2013) Mohit K. Sharma et al.   JOURNAL OF NEUROCHEMISTRY

Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease

(2013) Paula L. McClean et al.   NEUROPHARMACOLOGY

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

(2012) Kerry Hunter et al.   BMC NEUROSCIENCE

Parkinson's disease, insulin resistance and novel agents of neuroprotection

(2012) Iciar Aviles-Olmos et al.   BRAIN

Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection

(2012) Christian Hölscher   CNS DRUGS

An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease–associated Aβ oligomers

(2012) Theresa R. Bomfim et al.   JOURNAL OF CLINICAL INVESTIGATION

Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline

(2012) Konrad Talbot et al.   JOURNAL OF CLINICAL INVESTIGATION

Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats

(2012) Wei-Na Han et al.   NEUROBIOLOGY OF AGING

Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment

(2011) Suzanne Craft   ARCHIVES OF NEUROLOGY

Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease

(2011) Christian Hölscher   BIOCHEMICAL SOCIETY TRANSACTIONS

An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future

(2011) S. Madsbad et al.   DIABETES OBESITY & METABOLISM

Insulin resistance impairs nigrostriatal dopamine function

(2011) J.K. Morris et al.   EXPERIMENTAL NEUROLOGY

The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

(2011) P. L. McClean et al.   JOURNAL OF NEUROSCIENCE

Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain

(2011) A. Hamilton et al.   JOURNAL OF NEUROSCIENCE RESEARCH

Glucose tolerance status and risk of dementia in the community: The Hisayama Study

(2011) T. Ohara et al.   NEUROLOGY

A randomized, placebo-controlled trial of intranasal insulin in amnestic MCI and early Alzheimer's

(2010) Suzanne Craft et al.   Alzheimers & Dementia

Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet

(2010) Jill K. Morris et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance

(2010) D. W. Porter et al.   DIABETES OBESITY & METABOLISM

Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice

(2010) David W. Porter et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice

(2010) Simon Gengler et al.   NEUROBIOLOGY OF AGING

Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: A link between diabetes and Alzheimer's disease

(2009) Paula L. McClean et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system

(2009) Alison Hamilton et al.   NEUROREPORT

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

(2009) Y. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease

(2008) J.K. Morris et al.   BRAIN RESEARCH

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

(2008) J.-P. Courrèges et al.   DIABETIC MEDICINE

GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid

(2008) Victor A. Gault et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

A profile of impaired insulin degradation in relation to late-life cognitive decline: A preliminary investigation

(2008) Olivia I. Okereke et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

Glucagon-like peptide 1 receptor stimulation by exendin-4 reverses key deficits in distinct rodent models of Parkinson's disease

(2008) Alexander Harkavyi et al.   Journal of Neuroinflammation

Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling

(2008) Aileen M. Moloney et al.   NEUROBIOLOGY OF AGING

Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease

(2007) Göran Bertilsson et al.   JOURNAL OF NEUROSCIENCE RESEARCH